BR0308184A - Composição oftálmica compreendendo ascomicina - Google Patents

Composição oftálmica compreendendo ascomicina

Info

Publication number
BR0308184A
BR0308184A BR0308184-2A BR0308184A BR0308184A BR 0308184 A BR0308184 A BR 0308184A BR 0308184 A BR0308184 A BR 0308184A BR 0308184 A BR0308184 A BR 0308184A
Authority
BR
Brazil
Prior art keywords
ascomycin
ophthalmic composition
ophthalmic
blepharitis
treatment
Prior art date
Application number
BR0308184-2A
Other languages
English (en)
Inventor
Maggy Babiole Saunier
Jean-Claude Bizec
Michelle Pik-Han Wong
Shau-Fong Yen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27791682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0308184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0308184A publication Critical patent/BR0308184A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSIçãO OFTáLMICA COMPREENDENDO ASCOMICINA". A presente invenção refere-se às composições oftálmicas tópicas compreendendo uma ascomicina, por exemplo para o tratamento de doenças inflamatórias, tais como a blefarite.
BR0308184-2A 2002-03-04 2003-03-03 Composição oftálmica compreendendo ascomicina BR0308184A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36151502P 2002-03-04 2002-03-04
US40927502P 2002-09-09 2002-09-09
PCT/EP2003/002156 WO2003074054A1 (en) 2002-03-04 2003-03-03 Ophthalmic composition comprising ascomycin

Publications (1)

Publication Number Publication Date
BR0308184A true BR0308184A (pt) 2005-01-11

Family

ID=27791682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308184-2A BR0308184A (pt) 2002-03-04 2003-03-03 Composição oftálmica compreendendo ascomicina

Country Status (28)

Country Link
US (4) US20050220823A1 (pt)
EP (1) EP1482936B1 (pt)
JP (1) JP4740542B2 (pt)
KR (1) KR100992948B1 (pt)
CN (1) CN1297270C (pt)
AR (1) AR038628A1 (pt)
AT (1) ATE341326T1 (pt)
AU (1) AU2003218679B2 (pt)
BR (1) BR0308184A (pt)
CA (1) CA2477769C (pt)
CO (1) CO5611133A2 (pt)
DE (1) DE60308836T2 (pt)
DK (1) DK1482936T3 (pt)
EC (1) ECSP045277A (pt)
EG (1) EG24403A (pt)
ES (1) ES2274214T3 (pt)
HK (1) HK1071301A1 (pt)
IL (2) IL163657A0 (pt)
MX (1) MXPA04008571A (pt)
MY (1) MY137563A (pt)
NO (1) NO20044092L (pt)
NZ (1) NZ534690A (pt)
PE (1) PE20030828A1 (pt)
PL (1) PL210870B1 (pt)
PT (1) PT1482936E (pt)
RU (1) RU2322982C2 (pt)
TW (1) TW200305437A (pt)
WO (1) WO2003074054A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295647T3 (es) 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US20060115500A1 (en) * 2002-07-23 2006-06-01 Jithan Aukunuru Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
EP2238878A1 (en) 2009-04-09 2010-10-13 Nestec S.A. Beverage preparation device having a closing mechanism with force demultiplying means
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
BRPI1010907B8 (pt) * 2009-05-12 2021-05-25 Galenica Ab emulsão de óleo-em-água de mometasona e propileno-glicol
AU2010336518B2 (en) * 2009-12-22 2014-03-06 Abbvie Inc. ABT-263 capsule
CA2796045A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
RU2531937C2 (ru) * 2012-05-14 2014-10-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазной мази
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014153733A1 (en) * 2013-03-27 2014-10-02 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
JP6448545B2 (ja) * 2013-11-29 2019-01-09 ロート製薬株式会社 眼科用又は耳鼻科用水性組成物
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US10606760B2 (en) * 2017-08-23 2020-03-31 Samsung Electronics Co., Ltd. Nonvolatile memory devices and methods of controlling the same
EP3741367A1 (en) * 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69016515T2 (de) * 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
AU656145B2 (en) * 1990-09-04 1995-01-27 Astellas Pharma Inc. Ointments containing tricyclic compound
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
DE69328368T2 (de) * 1992-08-28 2000-08-10 Pharmos Corp., New York Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
ATE196734T1 (de) * 1993-08-18 2000-10-15 Alcon Lab Inc Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
CN100335063C (zh) * 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
FR2732598B1 (fr) * 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
FR2755852B1 (fr) * 1996-11-15 1998-12-24 Oreal Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
HUP0104452A3 (en) * 1998-04-27 2004-05-28 Fujisawa Pharmaceutical Co Medicinal compositions, containing tricyclo compounds
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
ATE281167T1 (de) * 1999-04-30 2004-11-15 Sucampo Ag Verwendung von makroliden zur behandlung von trockenen augen

Also Published As

Publication number Publication date
RU2322982C2 (ru) 2008-04-27
NO20044092L (no) 2004-09-27
PL370917A1 (en) 2005-06-13
WO2003074054A1 (en) 2003-09-12
CN1638769A (zh) 2005-07-13
AU2003218679A1 (en) 2003-09-16
JP2005529851A (ja) 2005-10-06
US20100113501A1 (en) 2010-05-06
CA2477769A1 (en) 2003-09-12
IL163657A (en) 2009-11-18
MY137563A (en) 2009-02-27
MXPA04008571A (es) 2004-12-06
KR100992948B1 (ko) 2010-11-08
AR038628A1 (es) 2005-01-19
JP4740542B2 (ja) 2011-08-03
US20120015971A1 (en) 2012-01-19
EP1482936A1 (en) 2004-12-08
CN1297270C (zh) 2007-01-31
ECSP045277A (es) 2004-10-26
KR20040094718A (ko) 2004-11-10
CO5611133A2 (es) 2006-02-28
RU2004129593A (ru) 2005-09-10
HK1071301A1 (en) 2005-07-15
NZ534690A (en) 2007-06-29
AU2003218679B2 (en) 2007-04-05
PE20030828A1 (es) 2003-11-04
ES2274214T3 (es) 2007-05-16
CA2477769C (en) 2011-01-18
US20050220823A1 (en) 2005-10-06
EP1482936B1 (en) 2006-10-04
DE60308836T2 (de) 2007-04-26
US20110152307A1 (en) 2011-06-23
PT1482936E (pt) 2007-01-31
DK1482936T3 (da) 2007-01-08
ATE341326T1 (de) 2006-10-15
DE60308836D1 (de) 2006-11-16
EG24403A (en) 2009-04-29
IL163657A0 (en) 2005-12-18
PL210870B1 (pl) 2012-03-30
TW200305437A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
BR0308184A (pt) Composição oftálmica compreendendo ascomicina
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
BRPI0512683A (pt) compostos anti-virais
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
ES2183937T3 (es) Inhibidores de la adhesion celular.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
TW200716596A (en) Substituted amide derivatives and methods of use
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
TNSN06228A1 (en) Compounds and methods of use
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
BR0313397A (pt) Inibidores de proteina cinase e usos destes
SE0301010D0 (sv) Novel compounds
UY29149A1 (es) Tiazolil-dihidro-indazoles
ATE490788T1 (de) Antivirale phosphonate analoge
CR10458A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
MA32811B1 (fr) Nouveaux composés
TW200509892A (en) Novel aminobenzophenone compounds
BRPI0413180A (pt) gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas
UY28144A1 (es) Agentes terapéuticos
EA200601462A1 (ru) Соединения для лечения заболеваний
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
MA32505B1 (fr) 5-alcynyl-pyrimidines

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 31/436, A61K 47/14, A61K 47/44, A61K 31/4353, A61P 27/02

Ipc: A61K 31/436 (2011.01), A61K 47/14 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.